Archive


Category: NHS

  • NICE expands cover for AZ’s high potassium drug Lokelma

    NICE has recommended extending funding via the NHS for AstraZeneca’s elevated potassium therapy Lokelma in new guidance, making it easier to receive the drug outside hospital settings. The new guidance means adults living with persistently high potassium levels in the blood – a condition known as hyperkalaemia – can now get repeat prescriptions for Lokelma […]

  • Labour peer’s AI healthcare firm Sensyne says cash is running out

    Data analytics company run by Paul Drayson says money could run out in weeks unless it finds emergency funding Shares in Sensyne Health plummeted after the healthcare technology company run by Paul Drayson, the former UK science and defence minister, said it could run out of money within weeks if it was unable to secure […]

  • UK medicines regulator approves Pfizer’s ‘life-saving’ Covid pill

    Paxlovid found to be ‘safe and effective’ at reducing hospitalisation and death among vulnerable adults Coronavirus – latest updates See all our coronavirus coverage UK regulators have approved Pfizer’s “life-saving” antiviral drug Paxlovid, which boasts nearly 90% success in preventing severe illness among vulnerable adults if taken soon after becoming infected with Covid-19. The Medicines […]

  • NICE backs Aimmune’s peanut allergy drug Palforzia for children

    Children in England with peanut allergies could be among the first in Europe to get access to Aimmune’s oral immunotherapy Palforzia, after the drugmaker agreed a supply deal with NHS England. The deal comes as cost-effectiveness watchdog NICE recommended Palforzia for NHS use in draft guidance published today which says the drug can be effective […]

  • NHS drug pledge broken for asthma sufferers and smokers, report reveals

    Exclusive: charities critical of failure to meet health plan for England, despite 2019 agreement A promise to ensure that people with severe asthma and smokers who want to quit can get the drugs they need has been broken by ministers and the NHS, a health service report reveals. Health charities criticised the persistent lack of […]

  • NICE gives Keytruda parity with Opdivo for adjuvant melanoma

    After three years of availability via the Cancer Drugs Fund (CDF), MSD’s checkpoint inhibitor Keytruda has now been approved for routine NHS use after surgery for people with melanoma to prevent the cancer returning. PD-1 inhibitor Keytruda (pembrolizumab) has been recommended by NICE for adjuvant treatment of adults with stage 3 melanoma that has spread […]

  • Booster COVID jabs offered to all adults in England

    The UK government has said it will step up its COVID-19 booster vaccination dramatically, with everyone in England aged over 18 offered a third dose before the end of the month. Westminster has promised additional support for the devolved administrations in Scotland, Wales and Northern Ireland to step up the booster campaign, and Scotland has […]

  • Boehringer-backed digital health academy set for launch in UK

    An online training academy that aims to raise the digital skills of NHS health and care workers is due to open its virtual doors next March, according to the Organisation for the Review of Care and Health Apps (ORCHA). The Digital Health Academy – developed with pharma company Boehringer Ingelheim – is part of a […]

  • Innovation and collaboration – the MHRA’s pandemic approach

    The pandemic has propelled issues for the pharmaceutical industry to the top of the political and public agenda, from clinical trial recruitment to the journey required for medicines or vaccines to reach patients. The public knows now more than ever that the Medicines and Healthcare products Regulatory Agency (MHRA) ensures the safety and quality of […]

  • NHS Digital, NHSX will be absorbed into NHS England

    It has been confirmed that NHS Digital and NHSX are to be incorporated into NHS England as part of a major shake-up of the health technology environment. The two organisations are going to be folded into NHS England’s new Transformation Directorate, which was formed earlier this year with the aim of bringing together digital and […]

  • NICE reaches a deal with Roche on access to oral SMA drug Evrysdi

    Roche’s oral treatment Evrysdi for the rare genetic disease spinal muscular atrophy (SMA) will be made available on the NHS in England, after NICE reached a three-year access agreement with the company. The cost-effectiveness agency had turned down Evrysdi (risdiplam) in draft guidance published in June, saying it was too expensive, but after negotiations with […]

  • NICE changes tack on NHS use of BMS’ myelofibrosis drug Inrebic

    After turning down routine NHS funding of Bristol-Myers Squibb’s Inrebic for bone marrow disorder myelofibrosis earlier this year, NICE now says the drug can be made available via the Cancer Drugs Fund. The health technology assessment (HTA) agency has recommended Inrebic (fedratinib) for treating disease-related splenomegaly (enlarged spleen) or other symptoms in myelofibrosis in patients […]

  • Parliamentary probe finds racism evidence in NHS sickle cell care

    Patients with sickle cell disease are facing racism in the NHS that is putting their lives a risk, claims a new report.  The All-Party Parliamentary Group (APPG) document – entitled No One’s Listening and partnered with the Sickle Cell Society – found “serious care failings” in acute services and evidence of attitudes underpinned by racism […]

  • NICE changes tack on ‘game changer’ rare cancer therapy Poteligeo

    NICE has reversed an earlier decision not to recommend NHS use of Kyowa Kirin’s Poteligeo for two rare blood cancers, ending the threat of a north-south divide in access to the drug in the UK. The cost-effectiveness watchdog has now backed Poteligeo (mogamulizumab) for adults in England and Wales with mycosis fungoides (MF) and Sézary […]

  • UK sets aside £248m to “digitise” NHS diagnostics

    The UK government has announced £248 million in spending over the next year for a project to make it easier for patient test results and scans to be shared between hospitals, labs and GP surgeries. The aim is to “digitise diagnostics care” across the NHS, reducing the time it takes to diagnose health problems and […]

  • Cautious welcome as NICE backs Forxiga for chronic kidney disease

    Tens of thousands of people with chronic kidney disease in England could be eligible for treatment with AstraZeneca’s SGLT2 inhibitor Forxiga, after NICE backed NHS use of the drug in draft recommendations. AZ said that the decision is a “milestone” in the treatment of CKD, becoming the first new treatment option for patients in nearly […]

  • Study shows HPV jab almost 90% effective at preventing cervical cancer

    Routine vaccination with human papillomavirus vaccines have resulted in an 87% reduction in cervical cancer cases in England, and could even see the need for smear tests phased out in future, according to a new study. The jabs with have been offered by the NHS to girls between the ages of 12 and 13 since […]

  • ‘No evidence’ conflicts of interest were considered in Greensill contracts – NAO

    National Audit Office reviewed NHS and pharmacy pay contracts given to David Cameron’s former adviser Whitehall’s independent watchdog has found “no evidence” that ministers or officials considered potential conflicts of interest before giving the disgraced financier Lex Greensill government contracts just months after he had left a job as a No 10 adviser. The National […]

  • Make locally led public health ‘business as usual’, says report

    COVID-19 proved the value of locally led, place-based public health – but teams need long-term funding and support if they are to take their place as an essential cog in the ICS machine. Local public health teams have been acting as “linchpins” during the pandemic, building cross-sector relationships to respond to the immediate crisis, as […]

  • NICE changes stance on Sanofi’s Dupixent for severe asthma

    18 months after saying “no”  to regular NHS funding for Sanofi and Regeneron’s Dupixent (dupilumab) for severe asthma in initial guidance, NICE has now backed the drug. The final appraisal document for Dupixent (dupilumab) has given the green light to use of the drug as an add-on maintenance therapy for people aged over 12 with […]

  • Digital therapeutics world first for Big Health in Scotland

    UK-based Big Health has passed a digital health milestone after Scotland became the first country to make anxiety and insomnia digital therapeutics available on a national basis. NHS Scotland will offer the digital health firm’s Sleepio and Daylight, and the cognitive behavioural therapy they provide, to all adults via their GP or online self-referral greatly […]

  • Consternation as NICE rejects Janssen MS drug Ponvory

    NICE has delivered its first verdict on NHS funding of Janssen’s oral multiple sclerosis drug Ponvory, and it’s not good news for patients with the disease waiting for new treatment options. In a provisional decision, NICE has said Ponvory (ponesimod) should not be available routinely on the NHS in England and Wales for relapsing forms […]

  • Google’s DeepMind faces suit over access to NHS patient records

    London-based firm Mishcon de Reya said it filed a claim in the U.K.’s High Court, alleging that Google’s access of 1.6 million people’s medical records broke privacy rules. NHS’ Royal Free London had struck an agreement with DeepMind in 2015 to build a system for alerting clinicians. 

  • NICE clears NHS use of Roche’s Tecentriq in bladder cancer

    NICE has recommended routine NHS access to Roche’s cancer immunotherapy Tecentriq for some bladder cancer patients, four years after it was first made available via the Cancer Drugs Fund (CDF). The PD-L1 inhibitor was initially turned down by NICE for a form of bladder cancer called urothelial carcinoma (UC), but Roche was encouraged to make […]

  • Yes, drugs are overprescribed: but it’s not the fault of GPs | Letters

    Fragmented care means patients can be put on drugs by many different specialists, says Charles Warlow, while Dr Wendy Outwin highlights the daily reality of prescribing medicines Ministers seem to have found yet another way to bash overburdened GPs (Government review finds 10% of drugs dispensed in England are pointless, 22 September). There is nothing […]

  • Early detection of cancers will require blood sweat and tears

    An NHS study of a new cancer blood test holds huge promise, but will not be without its challenges, says Snedden Campbell’s Ivor Campbell. The announcement that the NHS is taking part in a major new clinical trial for a blood test that could detect more than 50 cancers early has been welcomed as a […]

  • Keytruda backed by NICE for late-stage oesophageal cancer

    MSD’s Keytruda has become the first immunotherapy cleared by NICE for previously-untreated patients with advanced oesophageal cancer, making it an option for routine NHS treatment. Keytruda (pembrolizumab) has been given the green light for use alongside platinum- and fluoropyrimidine-based chemotherapy in patients with locally advanced or metastatic oesophageal cancer that cannot be treated with surgery. […]

  • Taking stock of NHS medicines optimisation

    Given the rising cost of medicines as a share of the NHS budget in England, the establishment of ICSs provides a timely opportunity to take stock on delivering medicines optimisation at local level, says NHS Gloucestershire CCG’s Ellen Rule. Medicines optimisation aims to improve health outcomes, service quality, and sustainability by ensuring patients are taking […]

  • NHS Deploys TytoCare’s Telehealth Solution to 14 Trusts Across UK

    What You Should Know: – TytoCare, an NYC-based all-in-one modular device and examination platform for AI-powered, on-demand, remote medical exams, today announced its expanded partnership with the NHS that will see the deployment of TytoCare’s telehealth solution across 14 organizations and 26 projects in Yorkshire and Humber, including Leeds Children’s Hospital, Sheffield Children’s, and nearly […]

  • NHS England starts largest ever trial of Galleri cancer blood test

    A blood test called Galleri that could detect dozens of different forms of cancer before symptoms appear will start trials by the NHS in England involving around 140,000 subjects. Volunteers aged between 50 and 77 are being sought to trial the diagnostic developed by California biotech Grail, which spun out of Illumina in 2016 and […]

  • NHS fast tracks access to Amgen’s just-approved KRAS cancer drug

    Amgen’s first-in-class KRAS inhibitor Lumykras has been approved in Great Britain and arrives already armed with an agreement to allow early access while its cost-effectiveness is appraised by NICE. The MHRA has approved Lumykras (sotorasib) for patients with previously treated locally advanced or metastatic non-small cell lung cancer (NSCLC) with the KRAS G12C mutation, and […]

  • AZ CEO Soriot urges caution on COVID booster doses

    The UK should think twice before backing widespread use of COVID-19 booster vaccinations, as to do so could place unnecessary burden on the NHS over the winter, according to AstraZeneca chief executive Pascal Soriot. In a letter to The Daily Telegraph newspaper with AZ’s head of biopharma R&D Mene Pangalos, Soriot write that the UK […]

  • NICE changes its mind on J&J’s Erleada in prostate cancer

    NICE has reversed its position on Johnson & Johnson’s oral prostate cancer therapy Erleada in patients with hormone-relapsed or hormone sensitive tumours, backing NHS use of the drug. The change of heart comes after J&J’s Janssen pharma unit offered an improved discount on Erleada (apalutamide), according to the cost-effectiveness watchdog in its final appraisal determination, […]

  • UK pledges £5.4bn to NHS to ease COVID-19 treatment backlog

    NHS England will get an extra £5.4 billion ($7.5 billion) in funding over the next six months to respond to COVID-19 and address a backlog in care caused by the pandemic, according to the UK government. The total includes £1 billion to get delivery of routine surgeries and treatments to patients delayed by COVID-19 back […]

  • Study backs benefit of insomnia DTx Sleepio on mental health

    A study has shown that people with anxiety or depression who used a digital therapeutic (DTx) for insomnia alongside psychological therapy, had better improvement in their mental health than those receiving therapy on its own. The study – published in the journal Behaviour Research and Therapy – tested the Sleepio app developed by digital health […]

  • NICE backs Cosentyx’ use in thousands of children with psoriasis

    NICE has recommended broadening NHS use of Novartis’ IL-17 inhibitor Cosentyx to include children aged six to 17 with severe plaque psoriasis. The cost-effectiveness agency says in draft guidance that Cosentyx (secukinumab) should be offered as an option to patients in this age bracket who either don’t respond to or cannot tolerate other systemic treatments. […]

  • NICE backs NHS use of Novartis’ cholesterol drug Leqvio

    Novartis’ cholesterol-lowering drug Leqvio will be made available on the NHS in England and Wales, and could help to prevent up to 30,000 deaths, according to NICE. The PCSK9-targeting oligonucleotide – which is already available in Scotland – requires dosing just twice a year and has been approved by the health technology assessment (HTA) agency […]

  • Novartis Signs an Agreement with NHS to Commercialize Leqvio (inclisiran) for the Treatment of Cardiovascular Disease

    Shots: The agreement follows the NICE recommendation to deliver Leqvio via a population health management approach for high-risk cardiovascular patients across England The NICE recommendation was based on Novartis’s ORION clinical research program including P- III trials ORION-9/10/11 evaluating the safety, efficacy, and tolerability of inclisiran in 3,600 patients with CVD which showed that the […]

  • NICE rejects J&J’ Darzalex regimen for multiple myeloma

    New guidance from NICE has rejected a combination regimen based on Johnson & Johnson’s Darzalex for a group of previously-untreated patients with multiple myeloma, a type of bone marrow cancer. The draft document covers the use of Darzalex (daratumumab) as an add-on to standard induction treatment with Takeda’s Velcade (bortezomib) plus thalidomide and dexamethasone given […]

  • Blueprints for UK pharma-NHS joint working

    Joint working could hold at least part of the answer to getting the NHS back on its feet after COVID, according to the ABPI. As the NHS begins to recover from the biggest crisis in its history, the biopharmaceutical industry is stepping up to the plate to offer its support and a new online repository of […]

  • NHS data sharing scheme “on hold” as millions opt out

    The NHS’ much-vaunted GP data-sharing initiative looks to be on a prolonged hiatus, with at least one report suggesting it has been hit by 1.2 million people choosing to opt out of the scheme in the space of two months. The General Practice Data for Planning and Research (GPDPR) is now on hold “with no […]

  • UK adults asked to record coughs to improve COVID detection

    Researchers in the UK are asking adults who have taken a COVID-19 test in the last 72 hours to record themselves coughing, breathing and speaking to help develop new ways to detect infection. The aim is to develop algorithms that could be used to detect COVID-19 remotely – for example before a PCR or lateral […]

  • A problem combination?

    Leela Barham takes stock of past NICE decisions for combinations to explore the scale of the reimbursement challenge for combination therapies. Combination therapies are now common in therapy areas like cancer. There have been cases where even if a new treatment used in combination were offered at zero cost to the NHS that it would […]

  • NICE changes stance on Lilly’s breast cancer dug Verzenio

    After rejecting Eli Lilly’s Verzenio for breast cancer therapy earlier this year, NICE has relented, recommending the drug for routine NHS use alongside hormonal therapy fulvestrant. A final appraisal document from the health technology assessment (HTA) agency backs the use of Verzenio (abemaciclib) alongside fulvestrant for the treatment of women with hormone receptor-positive, HER2-negative breast […]

  • Breast cancer drug approved for NHS after maker agrees discount

    Reversal of earlier rejection by Nice of abemaciclib – known as Verzenios – is welcomed by campaigners A breast cancer drug that was rejected for routine NHS use in England earlier this year has now been recommended by health officials after a discount was agreed with the manufacturer. The decision has been described as “fantastic […]

  • Collaborate to simplify cancer trials and accelerate post-pandemic recovery

    How could simplifying the administration of clinical trials help cancer diagnosis, care, and treatment levels to exceed pre-pandemic levels? Amanda Barrell reports from the ABPI Scotland cancer roundtable discussion. Work to get Scotland’s cancer services back to full strength following the pandemic has already begun, and the pharmaceutical industry has pledged to play its part. […]

  • Scotland backs Bavencio for bladder cancer after NICE says no

    Patients with bladder cancer in Scotland will be the first in the UK to claim access to maintenance treatment with Merck Serono and Pfizer’s Bavencio, ahead of their counterparts in England and Wales. The Scottish Medicines Consortium (SMC) has cleared NHS funding for Bavencio (avelumab) as a first-line maintenance therapy for people with advanced urothelial […]

  • Pfizer and Flynn accused of overcharging NHS for anti-epilepsy drugs

    Competition regulator the CMA alleges drugs firms abused dominant position with unfairly high prices Pharmaceutical companies Pfizer and Flynn have been accused by the UK’s competition watchdog of illegally overcharging the NHS for vital anti-epilepsy drugs by abusing their dominance in the market to raise prices overnight. The Competition and Markets Authority (CMA) has confirmed […]

  • Drug firm that hiked prices by 6,000% paid shareholders £400m

    Advanz Pharma and former private equity owners were fined £100m by markets watchdog A pharmaceuticals firm that inflated thyroid drug prices by up to 6,000% over a decade paid out more than £400m to shareholders and directors during the same period. London-based Advanz Pharma – and its former private equity owners HgCapital and Cinven – […]

  • Pain aggravation: the human cost of medicine price hikes

    After Advanz’s £100m fine over the price of its thyroid tablets, two people recount the difficulty of obtaining medication The UK’s competition watchdog has fined pharmaceutical company Advanz over £100m for inflating the price of its thyroid tablets by up to 6,000%. The exorbitant costs resulted in NHS clinical commissioning groups advising doctors not to […]

  • Pharma firm Advanz fined after thyroid drug price hike of 6,000%

    CMA found company’s ‘excessive and unfair’ prices cost NHS almost £30m extra over 10 years The UK’s competition watchdog has imposed fines of more than £100m on the pharmaceutical company Advanz and its former private equity owners after it was found to have inflated the price of its thyroid tablets by up to 6,000%. An […]

  • NHS sets aside £340m for new Innovative Medicines Fund

    NHS England has matched its financial backing of the Cancer Drugs Fund (CDF) with an equivalent pot of money for a new Innovative Medicines Fund (IMF) that will provide early access to cutting-edge medicines like cell and gene therapies. It has proposed that the IMF will work in the same way as the CDF, funding […]

  • UK funds ‘long COVID’ research drive as restrictions ease

    The UK government has provided almost £20 million ($27 million) in funding for 15 research projects aiming to look into the causes of long COVID, improve diagnosis and find new treatments for the condition. Long COVID is the term used to described people who still suffer from fatigue and other symptoms like breathlessness and muscle […]

  • UK funds ‘long COVID’ research drive as restrictions ease

    The UK government has provided almost £20 million ($27 million) in funding for 15 research projects aiming to look into the causes of long COVID, improve diagnosis and find new treatments for the condition. Long COVID is the term used to described people who still suffer from fatigue and other symptoms like breathlessness and muscle […]

  • UK drug companies fined £260m for inflating prices for NHS

    Watchdog issues warning after abuses that included paying would-be rivals to stay out of the market The UK’s competition watchdog has imposed fines totalling more than £260m on pharmaceutical companies after an investigation found that they overcharged the NHS for hydrocortisone tablets for almost a decade. The Competition and Markets Authority (CMA) found that the […]

  • Digitisation key to improving mental health services in England; report

    Faced with a looming mental health crisis, the UK government has been urged to invest in the digitisation of service provision across the NHS in England in a new report from think tank Future Care Capital. The study’s author – FCC’s head of policy and research Dr Peter Bloomfield, argues that there has been a […]

  • How digital pathways are changing healthcare

    As demonstrated throughout COVID, digital health is no longer experimental. Digital technologies are proving their value by allowing for better care, improved adherence and a more connected ecosystem between doctors, patients and pharma. Ampersand Health has been working in the space since 2015 and has seen it evolve from a niche approach with limited acceptance […]

  • Accelerating the adoption of innovation in the NHS

    Spreading innovation in the NHS is as much about fostering collaboration and building relationships as it is about designing new interventions and launching new technologies. Scaling up the adoption of new interventions and technologies in the NHS has always been something of a challenge. But a review of approaches used by the Academic Health Science […]

  • A life sciences vision to deliver health, wealth and resilience for the UK

    The ABPI’s chief executive Dr Richard Torbett outlines a new ‘vision’ and 10-year strategy for UK life sciences, launched by the government today. After an extraordinary year of science versus disease, the UK has cemented itself at the forefront of the global response to COVID-19. What has been achieved in just 18 months is nothing […]

  • UK body recommends COVID booster campaign in autumn

    The UK’s Joint Committee on Vaccination and Immunisation (JCVI) has recommended that the NHS should start a COVID-19 booster shot programme in September, to run alongside the annual flu vaccine drive.  The programme should run in two stages, initially targeting elderly and vulnerable people and frontline health and social care workers like the initial vaccination […]

  • UK body recommends COVID booster campaign in autumn

    The UK’s Joint Committee on Vaccination and Immunisation (JCVI) has recommended that the NHS should start a COVID-19 booster shot programme in September, to run alongside the annual flu vaccine drive.  The programme should run in two stages, initially targeting elderly and vulnerable people and frontline health and social care workers like the initial vaccination […]

  • Pandemic paves way for innovative hybrid healthcare

    While the heroic abilities of the NHS have been on display throughout the COVID-19 pandemic, the last year has also exposed the longstanding limitations and frailties of our underfunded healthcare system, says Maya Ward. With an estimated 100,000 unfilled posts and staff turnover expected to increase due to emotional exhaustion, the health service’s workforce stands […]

  • What’s affordable anyway? The future of NHS drug spending

    The single biggest monetary difference that can be made to the successor to the UK’s 2019 Voluntary Scheme for branded medicines pricing and access (VPAS) is to address the question of how the allowable growth rate for branded medicines is set. Now that VPAS has hit the mid-point and stakeholders are already thinking ahead to […]

  • NHS patient data upload delayed by two months, says UK

    The UK’s decision to set back the start date of a new patient data-sharing scheme by two months has been welcomed by privacy campaigners, who have claimed it was being rushed through without sufficient public scrutiny. The centralised database of medical records from 55 million people was due to come online on 1 July, but […]

  • Scotland backs rare blood cancer drug Poteligeo rejected by NICE

    A north-south divide has emerged in UK medicines access after the Scottish Medicines Consortium (SMC) okayed Kyowa Kirin’s Poteligeo for two rare blood cancers, a few weeks after the drug was turned in England by NICE. Poteligeo (mogamulizumab) has been backed by the SMC for adults living with mycosis fungoides (MF) and Sézary syndrome (SS), […]

  • Study finds “alarming” hike in antidepressant costs during COVID-19

    Researchers in the UK have found that there was a four million rise in prescriptions for antidepressants in England during 2020, adding £139 million to NHS costs. The team from the University of Huddersfield said the findings highlight an “urgent need” for new mental health strategies to make sure antidepressants are being used appropriately, particularly […]

  • EU’s COVID jab certificate scheme goes live in seven countries

    The first batch of EU countries have started recognising the vaccination status of travellers using digital vaccine certificates as the bloc moves towards freeing up travel ahead of the summer period. Germany, Greece, Bulgaria, Czech Republic, Denmark, Croatia and Poland are the first to start using the scheme, which will allow people who have been […]

  • Campaigners challenge NHS England’s latest plan to share patient data

    Remember the Care.data debacle? Now, a new move by NHS England to move the records of 55 million patients into a database that will be accessible by third-party companies is under fire by privacy campaigners, who claim it could be unlawful.  The new General Practice Data for Planning and Research (GPDPR) service was unveiled earlier […]

  • Healios raises £7m to expand digital mental health services

    Digital therapy specialist Healios has raised £7 million in new financing that will be used to expand its suite of mental health services, at a time when demand is soaring in the NHS. The London-based company has developed a virtual care platform that delivers a range of services targeted at children and young people with […]

  • UK highlights life sciences’ key role in post-COVID recovery

    The UK government used the Queen’s Speech to set out its ambition to make the country a leader in life sciences, garnering a warm response from industry groups.  The speech – an opportunity for Boris Johnson’s government to set out its plans for the year ahead after consolidating its position in last week’s local elections […]

  • AI in action: Report highlights the real-world benefits of AI in healthcare

    Joined up thinking is the key to converting AI-driven advances into real benefits for healthcare systems, say NHSX. Healthcare systems the world over have been facing the same challenges for some time – and the pandemic has only served to compound them. Aging populations, a growing number of people living with long-term conditions, and dwindling […]

  • NICE’s Office for Digital Health opens its doors

    UK cost-effectiveness agency NICE has this week officially opened the Office for Digital Health, one of the pillars of its five-year strategy out to 2026.  The in-house team of advisors has been set up by the health technology assessment (HTA) agency to spearhead its policy on digital health technologies (DHTs) – including apps, programmes and […]

  • Scotland backs NHS use of Alexion’s Ultomiris for rare disease aHUS

    NHS patients in Scotland with the rare disease atypical haemolytic uremic syndrome (aHUS) will now be able to access treatment with Alexion’s Ultomiris, ahead of their counterparts in England and Wales.  aHUS is an ultra-rare disease that can cause progressive injury to the kidneys via damage to the walls of blood vessels and blood clots […]

  • NHS app could be used as a vaccine passport

    The NHS app could be used a kind of vaccine passport, according to UK government sources, although it is unclear how far the project has progressed.  NHS England’s app is connected to GP services in England and linked to personal health data and as such could be used to show a person’s vaccine status before […]

  • AI is having a productive time in pharma and healthcare

    Two years ago the use of AI in pharma and healthcare looked to be quickly heading for what Gartner’s Hype Cycle model would term the Plateau of Productivity. After the COVID-powered digital transformations of both pharma and healthcare, there can be little doubt that artificial intelligence is already having a productive time across our sector. […]

  • Enhertu cleared for NHS use via Cancer Drugs Fund

    NICE has recommended the use of AstraZeneca and Daiichi Sankyo’s Enhertu in draft guidance, the first time the drug has been commissioned in any European country.  The UK health technology assessment (HTA) agency has backed Enhertu (trastuzumab deruxtecan) as a therapy for HER2 positive breast cancer which can’t be surgically removed or which has spread […]

  • Apple, Google block NHS contact tracing app update on privacy grounds

    A scheduled update to the NHS COVID-19 app has been blocked because it allows location tracking – something prohibited by Apple and Google, which developed some of the code it uses.  The new version of the app used in England and Wales was due to become available today to coincide with the relaxation of lockdown […]

  • Under-30s may have ‘small delay’ in getting Covid jab, says Jonathan Van-Tam

    England’s deputy chief medical officer says delay would be precaution against rare side-effect of blood clots Coronavirus – latest UK updates See all our coronavirus coverage People under 30 have been told there may be a “small delay” to when they will receive a coronavirus vaccine, given adults in that age group are now being […]

  • Wales forms authority to drive digital health in NHS

    A new organisation dedicated to increasing the use of digital health in the NHS in Wales has come into being, 18 months after the move was first unveiled by the Welsh government.  Digital Health and Care Wales (DHCW) – which has emerged from the now defunct NHS Wales Informatics Service (NWIS) – will be tasked […]

  • NICE backs Sobi’s Kineret for rare inflammatory disease

    The UK’s cost-effectiveness agency NICE has recommended that Sobi’s Kineret can be used to treat NHS patients with Still’s disease, a rare form of arthritis affecting children and adults. The final guidance concludes that interleukin-1 receptor antagonist Kineret (anakinra) can be used as a treatment for two forms of Still’s, namely systemic juvenile idiopathic arthritis […]

  • UK ED Dept. Shows Poor Usability for Major EHRs, Survey Finds

    What You Should Know: – Emergency doctors in the UK have said many electronic health records (EHRs) in use are close to being unacceptable, and this is likely to be having a negative impact on patient care. A national survey of more than 1500 members and fellows of the Royal College of Emergency Medicine ranked […]

  • Health tech and digital transformation lessons from the NHS

    In the year since the UK went into its first lockdown to limit the spread of COVID-19 the country’s health service has undergone an unprecedented digital transformation.  The NHS quickly scrambled to reduce face-to-face contact between patients and healthcare professionals, and manage demand for services that would soon be overstretched by dealing with the pandemic. […]

  • Cancer services should be rebuilt after COVID disruption, experts say

    There is a pressing need for a joined-up cancer strategy to reverse the impact of the COVID-19 pandemic, according to a new report from the UK’s pharma industry. The Association of the British Pharmaceutical Industry (ABPI) report said that the UK must be more ambitious with its cancer strategy if it is to compete with […]

  • Another UK hospital trials clinical comms platform Bleepa

    UK medical imaging firm Feedback has continued its expansion of its digital communication platform Bleepa with a one-year contract with a large UK hospital. The UK’s National Health Service is trying to phase out use of outmoded technologies such as pagers and faxes. But there are concerns that clinical teams are resorting to commercial apps […]

  • MHRA launches patient involvement pilot for drug applications

    The UK drugs regulator is now asking that all applications for new medicines or indications detail the efforts made to involve patients in the drug development process.  The voluntary scheme by the Medicines and Healthcare products Regulatory Agency (MHRA) aims to inject a dose of “patient centricity” into medicines development – something that has been […]

  • Barts Health puts real-time mobile data into staff hands

    England’s largest NHS Trust, Barts Health, is rolling out a new data analytics app that it says will improve patient care at its five London hospitals. The WeInform app will be used by more than 16,000 employees at the hospitals and various community units, including doctors and nurses, to tap into data that can be […]

  • Patrick Vallance: the adviser who spoke scientific truth to power

    The UK’s chief scientific adviser loves good food, enjoys a Scandi drama – and has been called ‘the richest civil servant in history’ Sir Patrick Vallance spent his 60th birthday at a podium in Downing Street, flanking Boris Johnson. Whatever plans he had were scrapped. Continue reading…

  • Patrick Vallance: the adviser who spoke scientific truth to power

    The UK’s chief scientific adviser loves good food, enjoys a Scandi drama – and has been called ‘the richest civil servant in history’ Sir Patrick Vallance spent his 60th birthday at a podium in Downing Street, flanking Boris Johnson. Whatever plans he had were scrapped. Continue reading…

  • Pharma must adapt to embrace the opportunities of a new-look NHS

    Fundamental changes to the way the NHS is structured and funded are afoot – and pharma needs to adapt to this new way of working. A new focus on “place” and the introduction of medicines registers are among the proposals in a new government white paper on the future of NHS England. Such changes may […]

  • Inside the UK’s leading efforts to restart clinical research

    A herculean national effort has seen 69% of paused studies due to COVID restarted under the National Institute for Health Research’s (NIHR) Restart Framework. Experts from the institute tell us how those numbers can be further boosted, and how lessons learned from the sector-wide collaboration will change UK research forever. There has been a remarkable […]

  • Double first for Scotland as it backs Roche’s Rozlytrek, Novartis’ Zolgensma

    The Scottish Medicines Consortium (SMC) has said Roche’s Rozlytrek can be used by NHS Scotland for the treatment of solid tumours with NTRK gene fusion mutations, regardless of where they occur in the body.  This is the second approval by the SMC for Rozlytrek (entrectinib), coming after the drug was cleared for use in ROS1-positive, […]

  • NICE says no to AZ’s Lynparza for prostate cancer

    NHS patients in England will not be able to get access to AstraZeneca’s PARP inhibitor Lynparza if they have BRCA-positive advance prostate cancer, according to draft guidance from NICE. The cost-effectiveness agency is assessing use of Lynparza (olaparib) in patients with tumours that carry BRCA1 or BRCA2 mutations who have previously been treated with the […]

  • NHS to use world’s most expensive drug to treat spinal muscular atrophy

    Zolgensma, which costs £1.79m for one-off treatment, will be available in England this year for the first time The world’s most expensive drug, which treats babies and young children with a rare and often fatal degenerative disorder, will be available this year for the first time on the NHS in England. Zolgensma, which costs £1.79m […]

  • Lilly’s Olumiant is first JAK drug backed by NICE for eczema

    Eli Lilly’s JAK inhibitor Olumiant has become the first drug in the JAK inhibitor class to be recommended for NHS use in England and Wales as a treatment for atopic dermatitis, also known as eczema. Olumiant (baricitinib) has been backed by cost-effectiveness agency NICE  to treat moderate to severe atopic dermatitis in adults who haven’t […]

  • Life-extending drug for incurable breast cancer approved for NHS use

    About 3,300 women a year may benefit from decision to approve ribociclib Women with incurable advanced breast cancer will be able to get a drug from the NHS that can potentially extend their life by almost eight months, under new guidance. The National Institute for Health and Care Excellence (Nice) has approved the drug – […]

  • Tribunal maintains Lexon’s £1.2m fine for breaking competition law

    Pharmaceutical wholesaler Lexon (UK) has lost its appeal against a £1.2 million fine in a case that accused it of exchanging commercially sensitive information about prices for nortriptyline tablets.  Lexon had appealed against a ruling by the UK’s Competition and Markets Authority (CMA) that it had exchanged information with King Pharmaceuticals and Alissa Healthcare Research […]

  • UK Launches World’s First COVID-19 Human Challenge Study

    What You Should Know: – This week, the United Kingdom (UK) will be the first country in the world to run a COVID-19 human challenge study, following approval from the UK’s clinical trials ethics body. – First Covid-19 human challenge study will begin within a month, after receiving ethics approval in the same week the […]

  • ‘It shows what we’re capable of’: the NHS’s vaccine triumph

    A huge effort has helped the UK provide 14m first doses of Covid vaccines in about two months Coronavirus – latest updates See all our coronavirus coverage In St Albans, GPs took over a former nightclub to provide Covid vaccinations every 20 seconds; in Carnforth, Lancashire, delivering jabs was helped by volunteers from the local […]

  • Wilmington Healthcare launches new platform to map the formulary landscape

    Healthcare intelligence provider Wilmington Healthcare has launched a new platform that enables pharma companies to develop a clear picture of formulary status across therapy areas and territories in the UK.   Known as InFormulary XD, the solution uses a unique blend of data and real-world evidence to provide an objective view of the status of […]

  • VPAS: Achievement so far on objectives for the economy and innovation

    In the third part of this series taking stock of the 2019 Voluntary Scheme for Branded Medicines Pricing and Access objectives, Leela Barham looks at the third VPAS objective that relates to the economy and innovation. The objectives for the economy and innovation are to: deliver a net benefit to the UK economy overall; and support the […]

  • UK targets COVID-19 variants with new order for CureVac jab

    The UK has agreed a 50 million-dose order for a COVID-19 vaccine with German biotech CureVac to support development of a shot that specifically targets emerging variants of the virus. The agreement will see the UK work with CureVac develop “new varieties of vaccines based on messenger RNA technology to be developed quickly against new […]

  • VPAS: Achievements so far on affordability

    In the second part of this series taking stock of the 2019 Voluntary Scheme for Branded Medicines Pricing and Access objectives, Leela Barham looks at the second VPAS objective that relates to affordability (spoiler alert: government gets millions in payments). The affordability objective is broken down further to: ensure that the Voluntary Scheme contributes to […]

  • UK vaccine strategy ‘paying off’ as latest trials boost stockpiles

    Pre-ordering of Janssen and Novavax means Britain has procured 247m successfully trialled jabs Coronavirus – latest updates See all our coronavirus coverage Britain has cemented its status as one of the world’s leading buyers of effective Covid vaccines after two more pharmaceutical companies reported positive trial results – potentially growing the UK stockpile by 90m […]

  • NICE reverses stance on Celgene’s Revlimid for myeloma maintenance

    NHS patients in England with newly-diagnosed multiple myeloma can be treated with Celgene’s Revlimid as maintenance therapy after a stem cell transplant, after new guidance from NICE. The cost-effectiveness agency has backed interim funding for Revlimid (lenalidomide) in this setting via the Cancer Drugs Fund (CDF), which provides temporary reimbursement for medicines until further data […]

  • Unlocking health data to improve oncology outcomes

    As the largest single-payer healthcare system in Europe, the UK’s National Health Service (NHS) has a uniquely beneficial health data and real-world evidence (RWE) environment. It’s one that has global potential to improve patient outcomes but efforts to harness the true potential of these information flows are only just beginning. The foundation for this is […]

  • UK is first European country to see COVID-19 deaths pass 100,000

    More than 100,000 people have died within 28 days of a positive COVID-19 test in the UK, the first European country to meet that grim milestone. The UK is only the fifth country after the US, Brazil, India and Mexico to pass that threshold, after a surge in cases following the holiday period around the […]

  • Nearly half of UK young people buy meds after consulting “Dr Google”

    It’s evident that relying on Google for a health diagnosis isn’t a good idea, but it seems a majority of UK people still do – and even buy medicines based on what they find. A new UK survey finds that overall 59% of 1,000 respondents Google their health symptom before consulting a doctor, with 16% […]

  • NICE backs broad use for Gilead/Galapagos arthritis pill Jyseleca

    Patients with rheumatoid arthritis (RA) in England will be able to get treatment with Gilead Sciences and Galapagos’ JAK inhibitor Jyseleca, after it was backed by cost-effectiveness agency NICE. Jyseleca (filgotinib) has been recommended for moderate and severe active RA in patients who have responded inadequately to intensive therapy with two or more conventional disease-modifying […]

  • The elective care conundrum – can digital innovation help?

    Karina Malhotra from Acumentice explores how digital tech and data could help address the NHS elective care backlog in 2021 and beyond. The repercussions of the COVID-19 pandemic are going to take a considerable time to repair and nowhere is this more pertinent than in NHS elective care. The impact on elective care has been […]

  • IoMT Is Improving Patient Access: We Must Avoid Creating New Barriers

    Heidi Sveistrup, CEO at Bruyère Research Institute Elza Seregelyi, Director at L-SPARK The Internet of Medical Things (IoMT) is changing the face of healthcare and has the potential to significantly improve patient access as well as system efficiencies. The adoption of telemedicine, for example, spurred on by the Covid-19 pandemic, has spread rapidly.  Forrester revised […]

  • Enabling new models of care: pursuing pharma’s partnership potential

    There is a huge, ongoing shift in how health and wellness is approached in the UK, and the changes will have important implications for NHS-industry partnerships. Transformative change is coming to the NHS and is set to radically alter how the UK’s health service cares for people at a population level. The NHS Long Term […]

  • Moderna’s COVID-19 vaccine is third approved in UK

    The UK has approved the Moderna coronavirus vaccine, hard on the heels of its go-ahead in Europe, although supplies are not expected to arrive for several weeks. Moderna’s mRNA-1273 is the third COVID-19 vaccine to be approved for use by the Medicines and Healthcare products Regulatory Agency (MHRA) and is the second mRNA vaccine after […]

  • IL-6 drugs do work in COVID-19, says UK, as it plans NHS use

    New data means that IL-6 drugs from Roche and Sanofi that had been all-but written off as coronavirus therapies will now be offered routinely to COVID-19  patients in intensive care in the UK. The renaissance of the two therapies comes on the back of the REMAP-CAP trial, which found that the IL-6 inhibitors RoActemra (tocilizumab) […]

  • Resourceful or risky? The UK’s controversial COVID-19 vaccine strategy

    As COVID-19 vaccines are hastily deployed in the UK for priority groups, a debate rages over the government’s controversial strategy to delay time between vaccine doses. When the UK announced the approval of the Pfizer-BioNTech and Oxford/AstraZeneca COVID-19 vaccines, it marked an exciting moment for the nation. After months of turbulent lockdown measures, the dawn […]

  • UK vaccine minister vows ‘massive uplift’ in number of jabs this week

    Nadhim Zahawi says ‘absolute focus’ is to get 13.9 million people inoculated by mid-February Coronavirus – latest updates See all our coronavirus coverage The UK vaccine minister, Nadhim Zahawi, has pledged a “massive uplift” in the number of coronavirus vaccinations carried out this week as he said reaching the government’s target of 13.9m jabs offered […]

  • Analysis: is it wise for England to mix and match Covid vaccines?

    US experts warn against plan to give different second jab if supplies run low Coronavirus – latest updates See all our coronavirus coverage The UK is setting the pace around the world in the approval and use of Covid vaccines but, while other countries watch intently, not all are yet prepared to embrace what looks […]

  • How is the Oxford Covid vaccine being deployed in England?

    With jab to be administered to public for first time, we look at key questions about its rollout Coronavirus – latest updates See all our coronavirus coverage The biggest vaccination programme in the UK’s history will receive a major boost on Monday, with the first use of the Oxford/AstraZeneca Covid vaccine. We answer some key […]

  • Vulnerable should all get COVID-19 shot before summer, says NHS chief

    NHS England’s chief executive Sir Simon Stevens has said that all vulnerable people over the age of 50 will be offered a COVID-19 vaccine by “late spring” in a message to healthcare workers. The prediction comes after the NHS announced on Christmas Eve that more than half a million people had received the Pfizer/BioNTech shot […]

  • NHS doctors ‘scrabbling’ to get vaccine amid alarm at Covid variant

    Many medics ‘frustrated’ about low priority given to frontline staff at high risk of infection Coronavirus – latest updates See all our coronavirus coverage Frontline NHS staff have been denied the Pfizer/BioNTech vaccine, leaving doctors alarmed and “scrabbling” to get immunised. A new survey reveals that almost two-thirds of medics who responded to it have […]

  • Health inequalities: A societal challenge that needs a cross-sector solution

    COVID-19 has laid the UK’s health inequalities bare and created an imperative for the NHS to develop a step-change in how it cares for diverse and marginalised communities. Health inequality is the “greatest societal challenge of our time”, according to a briefing document calling for a system-wide solution. The report was published by the Association […]

  • Covid vaccine arrives in UK hospitals ready for first jabs

    Medical director warns of great hurdles in largest vaccination campaign in UK history Coronavirus – latest updates See all our coronavirus coverage Batches of the Covid vaccine have begun to arrive in hospitals around the UK, ready for the first jabs on Tuesday in what NHS England’s medical director warned would be the largest and […]

  • Covid-19 vaccine ‘very safe and highly effective’, UK health chief says

    Vaccine safety message ‘vitally important’, head of medicines regulator tells Andrew Marr Show Coronavirus – latest updates See all our coronavirus coverage Public health messaging that people can have faith in the safety of coronavirus vaccines is “vitally important”, the leader of the body that has approved the Pfizer jab has said. Dr June Raine, […]

  • Navigating the NHS as a digital start-up

    We speak to finalists from the Greater Manchester Future of Health accelerator to find out how digital start-ups can overcome the challenges small companies face in bringing their technologies into the NHS. Right now the NHS is embracing digital to an extent no one could have foreseen a year ago – but that doesn’t mean […]

  • Zebra Medical Vision to Co-Develop AI-Based Models for Osteoporosis Early Detection & Prevention

    What You Should Know: – Zebra Medical Vision, the deep-learning medical imaging analytics company, and Scottish digital transformation consultancy Storm ID were chosen to co-develop new AI-based osteoporosis prevention solutions under EUREKA intergovernmental network.  – The UK-Israel research and development grant will be co-developed with clinical teams from NHS Greater Glasgow and Clyde and Assuta […]

  • Alliance and Boots donate dexamethasone to NHS

    The UK’s largest medical wholesaler and pharmacy have donated half a million dexamethasone tablets to support the effort against COVID-19. Alliance Healthcare and Boots, both part of Walgreens Boots Alliance, donated the 2mg Almus Dexamethasone tablets to the NHS to support it during the pandemic. The decision followed the findings of the RECOVERY trial, which […]

  • COVID-19 lessons for how pharma should support patient advocacy

    Trio Health’s Neil McGregor-Paterson asks whether the healthcare industry has paid enough attention to the patient voice during COVID-19 and looks at the many ways pharma can improve the patient experience across the sector going forward. Never has the health and care voluntary sector (HCVS) played such a critical role in supporting our nation´s health […]

  • A pivotal moment for digital health adoption

    Former chief digital officer for the NHS, Juliet Bauer, is now applying her experience to the private sector through video consultation firm Livi. She shares her thoughts on how well the NHS is integrating digital health and what the public and private sectors can do to further boost adoption. Bauer’s path to working in the […]

  • NICE says yes to Braftovi combination for colorectal cancer

    Two months after rejecting Pierre Fabre’s Braftovi for a rare form of metastatic colorectal cancer (mCRC), NICE has changed its mind, and now says the drug can be funded by the NHS in England, Wales and Northern Ireland. The cost-effectiveness agency has backed the combination of Braftovi (encorafenib) and Eli Lilly’s Erbitux (cetuximab) as a […]

  • Increasing patient engagement with UK clinical trials

    Pharmaceutical companies often struggle to actively involve patients in the design phase of clinical trials but doing so can have huge benefits for the sustainability and success of research. It can help address well established issues with studies, such as patient recruitment and retention, as well as reducing the need for additional trial protocol amendments. […]

  • Bridging the gap between pharma and the NHS in MS

    Janette Curlis is a Multiple Sclerosis Nurse Advisor (MSNA) at Biogen, helping to support the company’s Multiple Sclerosis (MS) field teams and developing patient and Healthcare Professional (HCP) materials. We spoke to her about being a bridge between pharma and the NHS and the challenges that are facing Multiple Sclerosis Nurses (MSNs) and patients today. […]

  • London’s digital health accelerator programme selects 20 new projects

    DigitalHealth.London has announced the latest 20 small and medium sized businesses selected for its digital accelerator programme. The programme selects digital solutions or services with the highest potential to meet the city’s health and social care challenges. This the fifth year the event has been running and the NHS delivered programme will see funding matched […]

  • After NICE okay, Scots denied access to Vifor’s Veltassa

    The Scottish Medicines Consortium (SMC) has ruled that there’s not enough evidence to support NHS funding of Vifor Pharma’s Veltassa for excess potassium in the blood (hyperkalaemia), even though patients in England can access the drug. It’s the second time that the SMC has rejected Veltassa (patiromer), having previously turned it down for hyperkalaemia in […]

  • Deep Dive: Digital Health Innovation 2020

    Most of the digital health experts we spoke to for this issue of Deep Dive made one thing clear – no one can really say what the future holds for digital tech in the pharma and healthcare industries. But this isn’t necessarily a bad thing – our interviewees also stressed that if companies can remain […]

  • Price cut leads NICE to back Novo Nordisk’s obesity drug Saxenda

    Novo Nordisk’s Saxenda has been recommended by NICE as a treatment for obesity, ending a 10-year drought in new drug therapies for weight management. The cost-effectiveness agency for England and Wales has recommended Saxenda (liraglutide) as a treatment option for people with a body mass index (BMI) of 35 or more, and who are also […]

  • Apple Rolls Out Health Records on iPhone to the UK, Canada

    Today, Apple announced the Health Records feature within the Health app is now available for users in the UK and Canada to securely view and store their medical records right on their iPhone, with their privacy protected at all times. Oxford University Hospitals and Women’s College Hospital has been selected the first healthcare institutions in […]

  • Roche working “around the clock” to tackle UK test supply problems

    Supplies of swabs for coronavirus and other critical NHS tests for diseases like cancer, diabetes and heart disease have been threatened by a failure at a facility operated by Roche. The company said the problems – which also include other items like reagents and screening kits – have resulted from a switch to a new […]

  • Roche working “around the clock” to tackle UK test supply problems

    Supplies of swabs for coronavirus and other critical NHS tests for diseases like cancer, diabetes and heart disease have been threatened by a failure at a facility operated by Roche. The company said the problems – which also include other items like reagents and screening kits – have resulted from a switch to a new […]

  • NHS coronavirus tests threatened by Roche supply chain glitch

    Pharmaceutical firm reports ‘significant drop in processing capacity’ of reagents, kits and swabs Coronavirus – latest updates See all our coronavirus coverage Concerns have been raised over the supply of vital testing materials for a range of conditions, including Covid-19, following a supply chain problem with the pharmaceutical company Roche. On Tuesday, Roche said it […]

  • GSK tells UK staff: turn off Covid test-and-trace app while at work

    Drugs company says infection controls at some of its sites are so secure the app is not needed Coronavirus – latest updates See all our coronavirus coverage The pharmaceuticals firm GlaxoSmithKline has told staff to switch off the contact tracing function that allows the NHS test-and-trace app to monitor the spread of Covid-19 while at […]

  • The value of good data to patients

    Better patient care pathways and models of care can be leveraged from the use of data, and the ability to collate and assess this information will drive more sustainable models of care, whilst unlocking the value of ‘longitudinal, real-world data’ as a resource for healthcare organisations, research and academia, policy advisors and pharma. There is […]

  • Introducing the new NIHR National Patient Recruitment Centres

    The five new NIHR National Patient Recruitment Centres (NPRCs) are set to shape the future of commercial clinical trials in the UK by offering new ways to conduct late-phase, large-scale research projects. One of the Sector Deal 2 commitments within the Government’s Life Sciences Industrial Strategy, the NPRCs are the first NIHR-funded research infrastructure that […]

  • From the archives: How Boots went rogue – podcast

    We are raiding the Audio Long Reads archives and bringing you some classic pieces from years past, with new introductions from the authors. This week’s article: Britain’s biggest pharmacy used to be a family business, dedicated to serving society. Now, many of the company’s own staff believe that its relentless drive for profit is putting […]

  • Why International Expansion Must Remain a Priority for Cerner, Epic, Allscripts, MEDITECH

    What You Should Know: – How the top US acute EHR vendors, namely Cerner, Epic, Allscripts, and MEDITECH (+85% share of US acute market in terms of revenues), have progressed on international expansion. As highlighted below, there is a significant variance amongst the big four in terms of revenue and share of business outside the US. Cerner has by far the highest revenue at more […]

  • Healthcare tech firms team up on consultation tools for GPs

    Three UK companies have combined their digital health technologies into a single remote consultation service for GP surgeries combining triage, video calls, patient messaging and treatment information. The platform combines eConsult’s digital triage tool – which was added to the NHS app a few weeks ago – with video consultation provided by Q Doctor and […]

  • NHS’ telemedicine ambitions approach a pivotal point

    The UK government has said it is vital to adopt telemedicine across the NHS in response to COVID-19 – but is the health service ready to fully embrace this digital tech? Dom Tyer investigates. The rapid digitalisation of life during COVID-19’s acute phase has had a huge impact on healthcare delivery during the pandemic, part […]

  • UK’s second go at a contact tracing app heads for pilot study

    After ditching its home-grown attempt at a coronavirus contact-tracing app for smartphones, the UK is ready to start pilot trials of a second version based on a platform developed by Apple and Google. The new NHS Test and Trace app is intended to be used as an add-on to the controversial national and local contact-tracing […]

  • NHS looks for digital pioneers to reshape services during pandemic

    A fellowship programme is looking for digital pioneers to design and lead service transformation projects in England’s NHS as the COVID-19 pandemic continues. DigitalHealth.London opens applications to its Digital Pioneer Fellowship programme, supporting change makers employed by NHS organisations in London to design and lead transformation projects underpinned by digital innovation. Sponsored this year by […]

  • UK warns drug firms to stockpile in case of Brexit disruption

    Companies should ensure six weeks’ worth of drugs for end of transition period, DHSC says Pharmaceutical companies should stockpile six weeks’ worth of drugs to guard against disruption at the end of the Brexit transition period, the government has said. The Department of Health and Social Care (DHSC) has written to medicine suppliers advising them […]

  • MSD’s David Peacock on moving UK healthcare forward

    David Peacock has worked across the world for MSD and other companies, and has now taken the helm of MSD’s UK & Ireland operations. In the latest article in our UK Leaders series, he tells us about the opportunities and challenges he is excited to take on in the region. Peacock has had a strikingly […]

  • UK should ramp up online GP consultations, advises report

    A large-scale shift towards online GP appointments could reduce no shows, save businesses up to £1.5 billion in lost employee work time, and free up considerable capacity, says a new report. The study – carried out by the Centre for Economics and Business Research (CEBR) – found that just 13% of consultations were carried out […]

  • The Guardian view on a women’s health scandal: under the skin | Editorial

    An official review of vaginal mesh and medicines in pregnancy reveals systemic weaknesses, and sexism too Greater openness about women’s bodies was one of the big themes of postwar feminism. Access to contraception and the right to terminate a pregnancy were crucial stepping stones on a path to liberation from a social order that for […]

  • Pelvic mesh scandal is what happens when men with power ignore women | Richard Vize

    Cumberlege report is a damning reminder of how arrogant, intimidating doctors have suppressed their patients’ views Julia Cumberlege’s report into avoidable harm inflicted by the healthcare system exposes an institutional inability to listen to patients in general and women in particular. Her investigation into decades of failure batters the reputation of the NHS, professional bodies, […]

  • Demand for flu vaccine soars as countries plan for second Covid-19 wave

    Manufacturers warn they will struggle to meet demand as governments seek to ease pressure on health services Coronavirus – latest updates See all our coronavirus coverage Fears of a second wave of coronavirus have sparked a global scramble for influenza shots from countries that hope to vaccinate great swathes of the population to reduce pressure […]